Iscucin Tiliae St.H ampoules, 10x1 ml

Information on Iscucin Tiliae Strength H

Iscucin Tiliae Strength H is a liquid dilution for injection containing the active substance *Viscum album* (Tiliae) *e planta tota* K. The composition of one ampoule includes *Viscum album* (Tiliae) *e planta tota* K Dil.Strength H 1 ml (HAB, Vs. 38).

Therapeutic indications

In accordance with the anthroposophic understanding of the human being and nature, Iscucin Tiliae may be used in adults to stimulate formative and integrative forces in order to resolve and reintegrate autonomous growth processes.These include, among others:

Malignant tumor diseases (including those with accompanying disorders of the blood-forming organs), benign tumor diseases, defined precancerous conditions, recurrence prophylaxis following tumor surgery, and chronic systemic diseases such as Crohn's disease or chronic joint disorders.

Contraindications

Iscucin Tiliae must not be used in cases of known allergy to mistletoe preparations, acute inflammatory or high-fever illnesses, chronic granulomatous diseases, active autoimmune diseases, during immunosuppressive therapy, or in cases of hyperthyroidism with tachycardia.

Precautions and warnings

In cases of primary brain and spinal cord tumors or intracranial metastases involving a risk of increased intracranial pressure, the preparations should be administered only after strict assessment of the indication and under close clinical monitoring.

Pregnancy and breastfeeding

The effects of the medicinal product on pregnancy, the development of the unborn child, childbirth, and the child's postnatal development—particularly the development of blood formation and the immune system in the fetus/infant—have not been studied.Consequently, the potential risk to humans is unknown.Caution should be exercised when using the product during pregnancy and breastfeeding.Consult your doctor before using this medicinal product.

Ability to drive and use machines

There is no information available regarding any impairment of the ability to drive or use machines.

Interactions with other products

No studies have been conducted on interactions with other immunomodulatory substances (e.g., thymus extracts).If such preparations are used concomitantly, cautious dosing and monitoring of appropriate immunological parameters are recommended.

Dosage and method of administration

Dosage is determined individually according to the doctor's instructions.The attending physician decides on the duration of treatment.In principle, there is no limit to the duration of treatment; it depends on the specific risk of recurrence and the patient's individual condition or clinical findings.Treatment should extend over several years, generally involving breaks of increasing length.

Errors in administration

Particular attention is drawn to the need for cautious dose escalation.Excessive dose escalation—especially skipping a dilution step at the lower strengths (e.g., from strength C to strength E)—can lead to allergy-like reactions requiring emergency measures.

Side effects

Like all medicines, Iscucin Tiliae can cause side effects, although not everybody gets them.A slight rise in body temperature and local inflammatory reactions at the subcutaneous injection site occur almost routinely at the start of therapy and indicate the patient's reactive response.Temporary, mild swelling of regional lymph nodes is likewise harmless.In the event of fever exceeding 38°C (possibly accompanied by fatigue, chills, a general feeling of illness, headache, and brief episodes of dizziness) or extensive local reactions exceeding 5 cm in diameter, the next injection should be administered only after these symptoms have subsided and at a reduced strength or dose.Fever induced by Iscucin injections should not be suppressed with fever-reducing medication.If fever persists for more than three days, an infectious process or tumor fever should be considered.Excessive local reactions can be avoided by using a lower strength of the preparation or a smaller dose volume.In such cases, the administration of 0.1–0.5 ml of the strength being used is recommended, employing a graduated 1 ml syringe.Localized or systemic allergic or allergoid reactions may occur (usually manifesting as generalized itching, urticaria, or rash; occasionally accompanied by angioedema, chills, shortness of breath, and bronchospasm; and in isolated cases, shock or erythema exsudativum multiforme); these require discontinuation of the preparation and the initiation of medical treatment. Activation of pre-existing inflammation and inflammatory irritation of superficial veins in the injection area are possible.Here, too, a temporary break in therapy is required until the inflammatory reaction subsides.The occurrence of chronic granulomatous inflammation (erythema nodosum) and autoimmune diseases (dermatomyositis) during mistletoe therapy has been reported.Symptoms of increased intracranial pressure in brain tumors/metastases during mistletoe therapy have also been reported.

Content

10 x 1ml

Pharmaceutical entrepreneur and manufacturer

WALA Remedy GmbH, Dorfstraße 1, 73087 Bad Boll/Eckwälden

No prescription is required for this product.